Venrock Adviser portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Venrock Adviser reported a $3.3 bn portfolio of 33 positions to the SEC as of the end of Q2 2026. Its largest positions are Apogee Therapeutics, ORKA, ERAS. During the quarter it opened Achieve Life Sciences and exited enGene Therapeutics and Tenax Therapeutics.
Sections with a free account
What changed this quarter
15 positions with a change (2 new, 5 added to, 5 trimmed, 3 sold); also, 2 entered through an IPO, 1 exited through an acquisition or merger. 7 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedParabilis MedicinesPBLS0.5% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Spyre Therapeutics−19%fewer sharesReduced6.9% → 8.0%
- Enliven Therapeutics−70%fewer sharesReduced2.5% → 0.8%
- enGene Therapeutics−1.0 ppof portfolioSold out1.2% → —
- Erasca+9.2%more sharesIncreased9.9% → 9.9%
- Tenax Therapeutics−0.8 ppof portfolioSold out1.0% → —
- CytomX Therapeutics−50%fewer sharesReduced1.8% → 0.6%
- Achieve Life Sciences+0.5 ppof portfolioNew— → 0.5%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Apogee Therapeutics34.2%
- Oruka TherapeuticsORKA12.0%
- ErascaERAS9.9%
- Spyre TherapeuticsSYRE8.0%
- Dianthus TherapeuticsDNTH3.5%
- Ocular TherapeutixOCUL3.1%
- Damora Therapeutics2.8%
- SavaraSVRA2.8%
- Jade BiosciencesJBIO2.2%
- Cogent BiosciencesCOGT1.9%
- Viridian TherapeuticsVRDN1.8%
- Vor BiopharmaVOR1.7%
- Dyne TherapeuticsDYN1.5%
- MAZE TherapeuticsMAZE1.4%
- Relmada TherapeuticsRLMD1.4%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 33
Q2 2026: 80%
Q2 2026: 5.1%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- ATLAS Infrastructure Partners (UK)Investment firm · $3.3 bn
- Vulcan Value PartnersInvestment firm · $3.3 bn
- Helikon InvestmentsInvestment firm · $3.3 bn
- Corvex ManagementInvestment firm · $3.2 bn
- Spruce House Investment ManagementInvestment firm · $3.4 bn
- Senvest ManagementInvestment firm · $3.4 bn